Assay Report
Methods · Standard Curves · QC · Results
Ultra-sensitive single-molecule digital immunoassay for quantifying Neurofilament Light chain (NfL) in plasma, serum, CSF, and tissue lysates down to sub-picogram per milliliter limits.
As the universal fluid biomarker of active neuroaxonal structural degradation, blood NfL provides an objective pharmacodynamic and longitudinal readout for preclinical neurodegenerative and neurotrauma pipelines. Creative Proteomics helps you build a fit-for-purpose sampling framework and delivers publication-ready concentration datasets.
Aligning biological questions, sampling kinetics, and analytical reserve before running the first sample.
Translating biofluid NfL measurements into clear research decisions requires structuring the analytical plan around the underlying biological timeline. Creative Proteomics establishes five universal design dimensions with each client prior to assay initiation:
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Kinetic Phase & Timeline | Acute injury spike, relapsing-remitting flare, or chronic progressive baseline drift | Aligns blood collection intervals with physiological release curves rather than arbitrary calendar dates. |
| Cohort Baseline Control | Pre-dose / pre-injury intra-individual baselines vs. age-matched parallel vehicle controls | Isolates true drug-mediated axonal rescue from natural age-associated biomarker elevation. |
| Multi-Marker Strategy | NfL as primary structural injury endpoint + contextual markers (e.g., glial fibrillary acidic protein [GFAP], p-Tau217) | Distinguishes general neuroaxonal loss from target-specific proteopathy or reactive astrogliosis. |
| Analytical Reserve & Replicates | Micro-volume allocation (15 μL net), duplicate confirmation, and orthogonal follow-up reserve | Prevents premature specimen exhaustion in valuable longitudinal small-animal cohorts. |
| Plate Allocation & Balancing | Randomizing treatment arms and paired longitudinal timepoints across analytical runs | Eliminates confounding between true experimental treatment effects and inter-plate assay variance. |
Evaluating analytical performance, multiplexing capacity, and data continuity across bioanalytical platforms for translational neuroscience programs.
| Technical Dimension | Conventional Plate ELISA | Luminex xMAP Multiplex | MSD ECL Platform | Quanterix Simoa HD-X |
|---|---|---|---|---|
| Analytical Sensitivity (LLOQ) | 15.0 – 50.0 pg/mL | 1.0 – 10.0 pg/mL | 1.0 – 5.0 pg/mL | 0.05 – 0.10 pg/mL (Sub-pg/mL) |
| Healthy Blood Basal Detectability | <25% (High non-detect rate) | 50% – 70% (Baseline dropout risk) | 70% – 85% (CSF optimal; plasma variable) | 100% Quantifiable across all cohorts |
| Sample Volume Consumption | 50 – 100 μL (Neat) | 25 – 50 μL | 25 – 50 μL | 15 μL net volume (1:4 dilution) |
| Multiplex Capacity | Singleplex (1 analyte) | High Multiplex (Up to 50–100 plex) | Medium Multiplex (1–10 plex) | Focused Low-Plex (1–4 plex) |
| Linear Dynamic Range | 2.0 – 2.5 logs | 3.0 – 3.5 logs | 4.0 – 5.0 logs | >4.5 logs (Digital + Analog) |
| Small Rodent Serial Sampling | Poor (Requires terminal pooling) | Moderate | Moderate | Excellent (Serial tail-vein / submandibular) |
| Primary Matrix Fit | In vitro cell supernatants | Serum, plasma, multi-species | CSF, tissue lysates, high-abundance biofluids | Peripheral blood (serum/plasma), micro-fluids |
Cross-platform transitions from legacy ELISA, Luminex, or MSD systems require structured bioanalytical method bridging. Differences in antibody clones, epitope accessibility, calibrator protein construct purity, and matrix dilution factors routinely generate a 1.2- to 1.6-fold numerical shift in absolute values, even when inter-platform rank correlations exceed r = 0.95.
Our Bridging Protocol: We analyze a representative pilot subset (15–20 paired baseline and elevated research specimens) in parallel across both platforms to establish a validated linear conversion algorithm, ensuring longitudinal dataset continuity across multi-year drug discovery campaigns.
Bioanalytical parameters established according to rigorous fit-for-purpose biomarker validation guidelines.
Monoclonal antibody pair specifically recognizes the central alpha-helical coiled-coil rod domain of the 68 kDa NfL subunit within the physiological 4:2:1 heteropolymer core, ensuring selective detection of active neuroaxonal structural release.
100% epitope sequence conservation across human, non-human primate (NHP), mouse, and rat species enables direct cross-species translation using identical calibration standards and antibody pairs without matrix-induced bias.
Rigorous clinical and preclinical cohort validation establishes robust linear correlation (r = 0.88–0.94) between peripheral blood plasma/serum NfL and paired CSF levels, validating serial blood sampling as a surrogate for invasive taps.
Specimens received on dry ice are barcode-logged, assessed for hemolysis/lipemia, and cataloged into monitored −80 °C storage.
Automated liquid handling performs sample dilution in matrix-matched assay diluent supplemented with heterophilic blockers.
Target NfL is captured onto paramagnetic beads functionalized with mAb 2.1, followed by biotinylated mAb 47.3 detector binding.
Bead-enzyme complexes (SBG) are loaded onto optical Simoa discs with 216,000 femtoliter wells, sealed with oil, and imaged for digital enzyme counting.
Average Enzymes per Bead (AEB) values are fitted against the calibration curve to output absolute pg/mL concentrations and QC statistics.
A standardized pre-analytical framework to evaluate specimen integrity and prevent non-biological variance.
| Pre-Analytical Parameter | Why It Matters for NfL Quantification | Intake Specification & Recommendation |
|---|---|---|
| Anticoagulant Selection | Heparin tubes cause polyanionic charge competition and reduce apparent signal by 10–15 %; K2-EDTA provides superior stability. | K2-EDTA plasma is strongly preferred; serum is acceptable if clotted consistently for 30–60 min at RT. |
| Centrifugation Timing | Delayed separation of whole blood at room temperature can cause non-specific platelet activation and minor cell debris background. | Centrifuge at 2,000 μg for 15 min at 4 °C within 60 minutes of collection; harvest platelet-poor upper phase. |
| Hemolysis Interference | Erythrocytes contain negligible NfL, but severe hemolysis (>5 g/L free Hb) alters sample viscosity and optical baseline. | Mild-to-moderate hemolysis is tolerated; samples with severe dark red discoloration will be flagged for optical absorbance. |
| Freeze-Thaw Stability | NfL is a robust analyte, but repeated freeze-thaw cycles (>5 cycles) can degrade protein complexes and reduce recovery. | Aliquot immediately into polypropylene cryovials; store at −80 °C; ship strictly on dry ice (minimum 5–8 kg). |
| Sample Net Volume | Micro-volume precision is essential for serial rodent blood draws without requiring animal sacrifice or sample pooling. | 15 μL net volume per well (30 μL recommended to support duplicate verification and analytical reserve). |
| Run Allocation & Balancing | In longitudinal studies, placing baseline and post-treatment samples on separate plates risks confounding treatment effects with batch variance. | We pre-plan plate layouts so that paired longitudinal timepoints and cohort groups are balanced across the same run. |
Empowering translational neuroscience, biomarker discovery, and drug candidate validation.
Quantify active motor neuron axonal breakdown and evaluate therapeutic neuroprotection in SOD1G93A and TDP-43 transgenic ALS mouse cohorts.
Track acute inflammatory demyelination spikes and evaluate candidate remyelination therapeutics in experimental autoimmune encephalomyelitis (EAE) models.
Quantify acute structural axonal breakage kinetics and long-term secondary neurotrauma progression in rodent fluid percussion injury (FPI) models.
Detect early peripheral and central neuroaxonal toxicity following paclitaxel, oxaliplatin, or bortezomib dosing in preclinical drug safety screening.
Assess structural axonal integrity and dorsal root ganglion (DRG) toxicity following high-dose systemic or intrathecal AAV vector delivery.
Execute non-terminal 15 μL serial tail-vein or submandibular blood sampling across surviving animal cohorts to generate continuous pharmacodynamic curves.
quality-controlled bioanalytical documentation and PhD-level consultation for every testing project.
Landmark studies establishing NfL as a sensitive, quantitative fluid biomarker of neuroaxonal injury.
Study Design Takeaway: Establishes blood NfL as an objective, etiology-agnostic structural endpoint for neuroprotection, independent of primary disease target.
Study Design Takeaway: Demonstrates pre-symptomatic NfL surge; highlights the necessity of pre-symptomatic baseline sampling in ALS mouse models.
Study Design Takeaway: Recommends aligning blood sampling frequency with acute flare windows and recovery phases in demyelinating EAE models.
Study Design Takeaway: Supports combining general axonal NfL with pathology-specific p-Tau217 to separate disease etiology from overall neurodegenerative magnitude.
Study Design Takeaway: Validates serial longitudinal sampling at 24h, 72h, 7d, and 14d post-head impact in animal TBI models.
Addressing common bioanalytical and project planning inquiries.
Cross-platform comparisons should be treated as a formal bridging exercise. While relative rankings and fold-changes correlate strongly (r > 0.95), absolute concentrations may show a systematic proportional shift (often 1.2- to 1.6-fold) due to differences in calibrator formulation and antibody avidity. We test a subset of bridging samples to establish a mathematical conversion factor.
Conventional ELISA has an LLOQ around 15–30 pg/mL, causing a high rate of non-detectable values in healthy control animals. Simoa achieves an analytical LLOQ of 0.10 pg/mL by isolating individual magnetic beads in 50-femtoliter microwells and applying digital Poisson statistics, ensuring 100% detectability across baseline and treated cohorts.
K2-EDTA plasma is strongly recommended for longitudinal animal studies due to high stability and rapid processing without clotting-induced variability. Serum is also fully compatible when processed under uniform 30–60 min clotting SOPs. We recommend maintaining the same collection tube type across all longitudinal study timepoints.
In the rare event that a sample falls below the functional LLOQ, we report both the raw Average Enzymes per Bead (AEB) value, the extrapolated concentration, and a clear qualitative flag (<LLOQ). We provide guidance on statistical imputation rules (e.g., LLOQ/2 or non-parametric analysis) appropriate for your study's statistical analysis plan.
To help us tailor the study plan, please provide the animal model or research cohort description, total sample count, biological matrix type, available net volume per sample, expected sampling schedule (longitudinal vs. cross-sectional), and whether orthogonal biomarkers (such as p-Tau217 or GFAP) are planned.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×